Furthermore, Liu et al. have observed that the 3-year OS rate among patients with R/R MM subjected to CAR T-cell therapy is markedly lower in the PTH group compared to the non-PTH group (41.5% vs. 66.5%, P < 0.001). The gene discussed is PTH; the disease is Miyoshi myopathy.